An observational study in Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS) and Cortical-basal Ganglionic Degeneration (CBGD), sponsored by University of California, San Francisco. Completed at 8 sites in 2 countries. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by University of California, San Francisco · Observational
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
Participants diagnosed with Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy, or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP); Healthy Volunteers.
Exclusion Criteria:
Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
Other: Observational Study
Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
Other: Observational Study
Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
Other: Observational Study
Tau-PET Brain Scan
Change from Baseline of Tau protein distribution in the brain.
Time frame: Baseline, 1-year, and 2-years.
Amyloid-PET Brain Scan
Presence of Amyloid in the brain at Baseline.
Time frame: Baseline
Brain Volume on MRI
Change from Baseline of brain tissue volume.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Progressive Supranuclear Palsy Rating Scale (PSPRS)
Change from Baseline of this rating scale.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Corticobasal Degeneration Functional Scale (CBDFS)
Change from Baseline of this rating scale.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Eye Movement Function
Change from Baseline of eye movement function.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Retinal Imaging
Change from Baseline of retinal thickness.
Time frame: Baseline, 6-months, 1-year, and 2-years.
UDS Neuropsychological Testing Battery, including supplemental FTLD Module
Change fromm Baseline of cognitive function.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Plan to share: Yes — Deidentified participant data are available by request .
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco